Daily Endocrinology Research Analysis
Analyzed 130 papers and selected 3 impactful papers.
Summary
Top findings span mechanistic, predictive, and therapeutic advances in endocrinology. A microbiota–metabolite–immune axis (dimethylglycine–Treg) was identified as a driver of recurrent implantation failure, oral semaglutide reduced heart failure events in people with type 2 diabetes and pre-existing heart failure, and a new FUMO score predicted Graves’ orbitopathy progression with strong discrimination.
Research Themes
- Microbiota–metabolite–immune mechanisms in reproductive endocrinology
- Cardiovascular outcomes with GLP-1 receptor agonists in type 2 diabetes
- Early risk stratification tools in autoimmune thyroid eye disease
Selected Articles
1. Endometrial microbiota-dimethylglycine-Treg cell axis affects endometrial receptivity in recurrent implantation failure.
Human endometrial microbiota in RIF differs in diversity and composition and is linked to a metabolomic signature featuring reduced dimethylglycine. Transplanting RIF-associated endometrial microbiota into rats impaired implantation, reduced uterine Treg cells, and downregulated Hoxa-10/Lif; dimethylglycine supplementation mitigated these effects. The study identifies a microbiota–DMG–Treg axis that compromises endometrial receptivity.
Impact: This work uncovers a mechanistic immunometabolic pathway linking endometrial dysbiosis to implantation failure and provides a tractable target (dimethylglycine) for intervention.
Clinical Implications: Endometrial microbiota profiling and dimethylglycine status could inform risk stratification in RIF. DMG supplementation and microbiome-targeted therapies warrant evaluation as adjuncts to improve endometrial receptivity.
Key Findings
- Endometrial microbiota diversity and uterine lavage fluid microbiota significantly differed between RIF and controls (alpha P=0.022; beta both P<0.05).
- Endometrial metabolomics showed 19 metabolites decreased in RIF, including dimethylglycine.
- Transplanting RIF-associated EnM into rats reduced implantation sites, decreased uterine Treg cells, and downregulated Hoxa-10 and Lif.
- Dimethylglycine supplementation mitigated Treg reduction and receptivity impairment induced by dysbiotic EnM.
Methodological Strengths
- Integrative multi-omics (microbiota and metabolomics) in human tissue with correlation analyses
- Causal inference supported by in vivo microbiota transplantation and functional rescue by DMG
Limitations
- Human sample size and cohort details are not fully specified; generalizability requires validation
- Translational gap remains: findings are preclinical in animal models without clinical interventional trials
Future Directions: Validate the EnM–DMG–Treg axis in larger human cohorts; conduct randomized trials of DMG supplementation and microbiome-targeted therapies to improve implantation in RIF.
Recurrent implantation failure (RIF) poses a substantial challenge in assisted reproductive technologies, causing serious psychological burden and economic pressure to patients with infertility. However, the pathogenesis of RIF remains unclear; therefore, in-depth research on RIF is crucial for guiding clinical treatment. Recent studies have indicated that reproductive tract microbiota imbalance is closely related to RIF, making it a new and promising research direction to explore. The present study shows that during the secretory phase, alpha diversity of the endometrial microbiota (EnM) significantly differed (P=0.022) between the RIF and control groups. Moreover, beta diversity analysis found significant differences in both the EnM and uterine lavage fluid microbiota (UfM) (both P<0.05). Further comparing the endometrial tissue metabolites of the RIF and control groups in the secretory phase, 34 metabolites were significantly increased, while 19 others, such as dimethylglycine (DMG), were significantly decreased in the RIF group. Correlation analysis revealed significant correlations between differentially abundant microbiota and metabolites in the endometrium. Furthermore, transplantation of EnM from the RIF group into the uterine cavity of SD rats significantly altered the microecological environment of the uterine cavity, decreasing Hoxa-10 and Lif and reducing embryonic implantation sites. Further exploration of the mechanism revealed that this transplantation decreased the proportion of uterine regulatory T (Treg) cells and the expression of DMG. Additionally, DMG supplementation is expected to mitigate the reduction in Treg and the impairment of endometrial receptivity caused by endometrial tissue microbiota disorders. Therefore, alterations in EnM in patients with RIF may alter endometrial metabolites, decrease Treg-cell proportions, affect endometrial receptivity, and ultimately induce recurrent implantation failure.
2. Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
In 9,650 adults with T2D and ASCVD/CKD, oral semaglutide reduced the composite of HF hospitalization, urgent HF visits, or CV death among those with baseline HF (HR 0.78), with a marked effect in HFpEF (HR 0.59) and no signal in HFrEF. MACE reduction was consistent regardless of HF history, and serious adverse events were similar to placebo.
Impact: This secondary analysis extends GLP-1 RA cardiovascular benefits to HF morbidity, highlighting oral semaglutide as a potential strategy to reduce HF events, particularly in HFpEF.
Clinical Implications: For T2D patients with established HF, especially HFpEF, consider oral semaglutide to lower HF events alongside standard of care. Findings support guideline discussions on GLP-1 RA selection when HF risk is prioritized.
Key Findings
- Composite HF outcome was reduced with oral semaglutide vs placebo in participants with baseline HF (HR 0.78, 95% CI 0.63-0.96).
- HFpEF subgroup showed pronounced benefit (HR 0.59, 95% CI 0.39-0.86), whereas HFrEF did not (HR 0.98, 95% CI 0.70-1.38).
- MACE reduction was consistent regardless of HF history; serious adverse events were similar between groups.
Methodological Strengths
- Large, double-blind, placebo-controlled randomized framework with prespecified HF composite outcome
- Subgroup analyses by HF phenotype (preserved vs reduced ejection fraction)
Limitations
- Secondary analysis with borderline interaction (P=0.06) between HF history strata
- HF subtype classification incomplete for all participants; trial not primarily designed for HF endpoints
Future Directions: Dedicated HF outcome trials with GLP-1 RAs, mechanistic studies in HFpEF, and head-to-head comparisons vs SGLT2 inhibitors in T2D with HF.
IMPORTANCE: Heart failure (HF) is a common complication of type 2 diabetes (T2D). Oral semaglutide reduced the risk of major adverse cardiovascular (CV) events (MACE; comprising CV death, nonfatal myocardial infarction, or nonfatal stroke) in people with T2D in the SOUL trial, but the impact on HF outcomes in these participants is unknown. OBJECTIVE: To evaluate the effect of oral semaglutide on HF events, MACE, and safety among participants with or without HF at baseline. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, which was conducted at 444 centers in 33 countries. Participants were enrolled from June 17, 2019, to March 24, 2021, and had T2D and atherosclerotic CV disease and/or chronic kidney disease, stratified according to the presence or absence of HF history at baseline. Data were analyzed from December 2024 to August 2025. INTERVENTION: Once-daily oral semaglutide or placebo in addition to standard of care. MAIN OUTCOMES AND MEASURES: Prespecified composite HF outcome (time to first occurrence of HF hospitalization, urgent HF visit, or CV death). RESULTS: Overall, 9650 participants (median [IQR] age, 66.0 [61.0-72.0] years; 2790 [28.9%] female) were randomized, with a mean (SD) follow-up of 47.5 (10.9) months. Of these participants, 2229 (23.1%) had HF history (991 [10.3%] with preserved ejection fraction, 592 [6.1%] with reduced ejection fraction, and 646 [6.7%] with unknown subtype). For participants with HF at baseline, the hazard ratio (HR) for risk of the composite HF outcome with oral semaglutide vs placebo was 0.78 (95% CI, 0.63-0.96) and was 1.01 (95% CI, 0.84-1.20) in those without HF at baseline (P for interaction = .06). Among participants with HF, the HR was 0.59 (95% CI, 0.39-0.86) in those with preserved ejection fraction and 0.98 (95% CI, 0.70-1.38) in those with reduced ejection fraction. There was no heterogeneity in the risk reduction of MACE with oral semaglutide in participants with HF history (HR, 0.83; 95% CI, 0.68-1.01) or without HF history (HR, 0.86; 95% CI, 0.75-0.98) (P for interaction = .77). Serious adverse event occurrence among participants with HF was similar with oral semaglutide (594 [53.8%]) and placebo (642 [57.1%]). CONCLUSIONS AND RELEVANCE: In this secondary analysis of the SOUL randomized clinical trial, among individuals with T2D, atherosclerotic CV disease, and/or chronic kidney disease, a reduction of HF events was observed with use of oral semaglutide compared with placebo in those with a history of HF, without increasing the risk of serious adverse events. These data support the potential benefit of oral semaglutide in reducing HF events in people with T2D and HF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03914326.
3. Subclinical Ocular Alterations in Graves' Disease: The FUMO Score, a New Tool to Predict Graves' Orbitopathy Progression.
The FUMO score combines visual functional tests and orbital ultrasound (0–8 points) to stratify GO risk. Over 24 months, medium–high FUMO strata showed higher incidence, activity, and severity of GO. TRAb and FUMO were the strongest independent predictors, with AUC 0.84 and PPV/NPV of 73%/72%.
Impact: Provides a practical, validated bedside score using widely available ocular assessments to identify GD patients at risk for GO progression, enabling earlier monitoring and intervention.
Clinical Implications: In GD without overt GO, incorporate FUMO (with TRAb/FT3 and smoking assessment) to triage follow-up intensity and consider early preventive strategies (e.g., smoking cessation, selenium in mild disease, prompt referral to ophthalmology).
Key Findings
- FUMO score integrates visual function (0–3) and orbital ultrasound (0–5) into a total risk score of 0–8.
- Medium–high FUMO risk was associated with higher incidence, activity, and severity of GO over 24 months.
- TRAb and FUMO were the strongest independent predictors of GO; model AUC was 0.84 with PPV 73% and NPV 72%.
Methodological Strengths
- Prospective 24-month follow-up with predefined functional and morphological metrics
- Multivariable modeling with calibration and discrimination analyses (AUC 0.84)
Limitations
- Moderate sample size and lack of external validation
- Observational design without interventional testing of risk-guided strategies
Future Directions: External validation across diverse populations; assess whether FUMO-guided monitoring or early therapy improves GO outcomes.
INTRODUCTION: This observational investigation aimed to assess the accuracy of a novel score in predicting the onset of overt Graves' orbitopathy (GO) in Graves' disease (GD) patients. MATERIALS AND METHODS: A total of 156 consecutive GD patients without GO were enrolled. As control group, 45 patients with non-autoimmune hyperthyroidism were included. At baseline, an ophthalmological evaluation was performed, including 1) visual function tests; 2) orbital ultrasound. After 24 months, the occurrence of GO was assessed in all patients. RESULTS: At baseline, a score from 0 to 3 and a score from 0 to 5 were assigned based on the results of visual function tests and the results of orbital ultrasound, respectively. The scores were combined into an overall FUnctional and MOrphological risk score (FUMO score) (0-8 points), classifying patients as low risk (score 0-2) or medium-high risk (score 3-8). After 24 months, the two risk groups were compared for differences in: 1) presence/absence of GO; 2) GO activity and severity.Patients in the medium-high risk group developed overt GO more frequently than those in the low-risk group. Additionally, GO was more frequently active and moderate-to-severe in medium-high risk patients.Multiple logistic regression showed that TRAb levels and FUMO were the strongest independent predictors of GO, with higher FT3 and smoking habit levels also conferring increased risk. The model demonstrated good calibration and discrimination (AUC=0.84; p<0.0001), with high positive (73%) and negative (72%) predictive value. CONCLUSIONS: Subclinical ocular alterations can predict the progression of GO in patients with GD. The FUMO score, particularly when combined with TRAb and FT3 levels, reliably identifies patients at risk of developing overt GO, supporting its use for early risk stratification.